Corneal cross-linking

Majed Alkharashi; Ziyad Alharbi; Yassine J. Daoud

doi:10.1586/17469899.2014.927310

Corneal cross-linking

Majed Alkharashi, Ziyad Alharbi, Yassine J. Daoud

School of Medicine

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus. Since then, the procedure showed promising results in post-LASIK ectasia. One of the new applications of CXL is in infectious keratitis. In this review, the authors discuss the applications of CXL and cover the new advances in this field. CXL is still not US FDA approved in the USA.

Original language	English (US)
Pages (from-to)	305-313
Number of pages	9
Journal	Expert Review of Ophthalmology
Volume	9
Issue number	4
DOIs	https://doi.org/10.1586/17469899.2014.927310
State	Published - Aug 2014

Keywords

corneal collagen cross-linking
corneal ectasia
infectious keratitis
refractive surgery

ASJC Scopus subject areas

Biomedical Engineering
Ophthalmology
Optometry

Access to Document

10.1586/17469899.2014.927310

Cite this

@article{bb69aecfdb7047ed966ca74ce1c85087,

title = "Corneal cross-linking",

abstract = "Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus. Since then, the procedure showed promising results in post-LASIK ectasia. One of the new applications of CXL is in infectious keratitis. In this review, the authors discuss the applications of CXL and cover the new advances in this field. CXL is still not US FDA approved in the USA.",

keywords = "corneal collagen cross-linking, corneal ectasia, infectious keratitis, refractive surgery",

author = "Majed Alkharashi and Ziyad Alharbi and Daoud, {Yassine J.}",

note = "Funding Information: This study was supported in part by an unrestricted departmental grant to Emory University Department of Ophthalmology and to the Baylor College of Medicine, Cullen Eye Institute, from Research to Prevent Blindness, Inc .",

year = "2014",

month = aug,

doi = "10.1586/17469899.2014.927310",

language = "English (US)",

volume = "9",

pages = "305--313",

journal = "Expert Review of Ophthalmology",

issn = "1746-9899",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Corneal cross-linking

AU - Alkharashi, Majed

AU - Alharbi, Ziyad

AU - Daoud, Yassine J.

N1 - Funding Information: This study was supported in part by an unrestricted departmental grant to Emory University Department of Ophthalmology and to the Baylor College of Medicine, Cullen Eye Institute, from Research to Prevent Blindness, Inc .

PY - 2014/8

Y1 - 2014/8

N2 - Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus. Since then, the procedure showed promising results in post-LASIK ectasia. One of the new applications of CXL is in infectious keratitis. In this review, the authors discuss the applications of CXL and cover the new advances in this field. CXL is still not US FDA approved in the USA.

AB - Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus. Since then, the procedure showed promising results in post-LASIK ectasia. One of the new applications of CXL is in infectious keratitis. In this review, the authors discuss the applications of CXL and cover the new advances in this field. CXL is still not US FDA approved in the USA.

KW - corneal collagen cross-linking

KW - corneal ectasia

KW - infectious keratitis

KW - refractive surgery

UR - http://www.scopus.com/inward/record.url?scp=84904651708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904651708&partnerID=8YFLogxK

U2 - 10.1586/17469899.2014.927310

DO - 10.1586/17469899.2014.927310

M3 - Review article

AN - SCOPUS:84904651708

SN - 1746-9899

VL - 9

SP - 305

EP - 313

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

IS - 4

ER -

Corneal cross-linking

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this